01—Abstract
Summary
Summary of the 10-K filed June 25, 2021. Cited figures are marked; the original filing is the authoritative source.
Medtronic plc's 2021 10-K filing indicates a company navigating the complexities of the COVID-19 pandemic while focusing on strategic growth and operational efficiency.
The company reported a total net sales increase of 4% to $30.1 billiona, driven by a recovery in medical procedure volumes globally as pandemic restrictions eased, although recovery was uneven across geographies and product lines. Key segments like Cardiovascular and Medical Surgical showed modest growth, while Neuroscience saw a 6% increase. The Diabetes unit experienced a 2% rise in sales.
Medtronic emphasized its commitment to innovation and leveraging technology, including AI and data analytics, to tailor therapies and improve patient care. The company also highlighted its ongoing restructuring efforts, including the 'Enterprise Excellence' program and a new 'Simplification' initiative aimed at streamlining operations and enhancing competitiveness. Despite global economic uncertainties and competitive pressures, Medtronic maintained a strong financial position, with significant cash reserves and a robust credit facility, underscoring its resilience and ability to invest in future growth and shareholder returns.
02—Key points
Key Highlights
- Total net sales increased by 4% to $30.1 billion, reflecting a recovery in global medical procedure volumes post-COVID-19.
- The Cardiovascular segment saw a 3% increase in net sales to $10.8 billion, driven by Cardiac Rhythm & Heart Failure products, though Structural Heart & Aortic was flat and Coronary & Peripheral Vascular declined.
- Medical Surgical segment net sales grew by 5% to $8.7 billion, largely due to a strong performance in Respiratory, Gastrointestinal, & Renal products, boosted by COVID-19 related demand.
- Neuroscience segment sales increased by 6% to $8.2 billion, with growth across all divisions, supported by the recovery in procedure volumes.
- The company reported Non-GAAP diluted earnings per share of $4.44, an improvement from the previous fiscal year, indicating effective management of operational performance.
- Medtronic maintained a strong liquidity position with $3.6 billion in cash and cash equivalents and $7.2 billion in current investments, alongside a $3.5 billion credit facility.
- Significant restructuring efforts, including the 'Enterprise Excellence' and 'Simplification' programs, are underway to drive long-term efficiency and competitiveness, with associated charges noted.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2021, Medtronic plc kept $0.12.
- Revenue$30.12B100.0%
- Cost of revenue−$10.48B34.8%
- Gross profit$19.63B65.2%
- Operating costs−$15.15B50.3%
- Operating income$4.48B14.9%
- Interest, other & tax−$854.0M2.8%
- Net income$3.63B12.1%
Where FY2021 revenue went
$30.12B- Cost of revenue: $10.48B, 35% of revenue
- SG&A: $10.15B, 34% of revenue
- Other operating costs: $5.00B, 17% of revenue
- Net income: $3.63B, 12% of revenue
- Interest, other & tax: $854.0M, 2.8% of revenue
Kept 12% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2021filed June 25, 2021Financial Statements
FY2021 against FY2020
| Line item | FY2021FY2020 | Change |
|---|---|---|
| Revenue | $30.12B$28.91B | +4.2% |
| Cost of Revenue | $10.48B$9.42B | +11.2% |
| Gross Profit | $19.63B$19.49B | +0.7% |
| SG&A Expenses | $10.15B$10.11B | +0.4% |
| Operating Income | $4.48B$4.79B | −6.4% |
| Interest Expense | $925.00M$1.09B | −15.3% |
| Net Income | $3.63B$4.81B | −24.5% |
| EPS (Basic) | $2.68$3.57 | −24.9% |
| EPS (Diluted) | $2.66$3.54 | −24.9% |
| Shares Outstanding (Basic) | 1.34B1.34B | +0.3% |
| Shares Outstanding (Diluted) | 1.35B1.35B | +0.2% |
05—Questions
Frequently Asked Questions
How did Medtronic's financial performance fare in fiscal year 2021, particularly in the context of the COVID-19 pandemic?
Medtronic reported a 4% increase in total net sales to $30.1 billion for fiscal year 2021. This growth was primarily driven by the recovery of medical procedure volumes globally as pandemic-related restrictions eased, although the recovery was uneven across different regions and product lines. Despite the ongoing impact of COVID-19, the company demonstrated resilience, with improved Non-GAAP diluted earnings per share of $4.44.
What are the key growth drivers and challenges for Medtronic's major business segments?
In the Cardiovascular segment, Cardiac Rhythm & Heart Failure products, including the Micra leadless pacing system, drove growth. However, Structural Heart & Aortic sales were flat, impacted by a product recall, and Coronary & Peripheral Vascular sales declined due to pricing pressures in China. The Medical Surgical segment saw strength in Respiratory, Gastrointestinal, & Renal products, partly due to COVID-19 demand, while Surgical Innovations experienced a slight decline. The Neuroscience segment showed growth across its divisions, benefiting from procedural recovery. The Diabetes segment experienced modest growth, with strength in international markets for the MiniMed 780G system.
What is Medtronic doing to improve its operational efficiency and competitiveness?
Medtronic is undertaking significant restructuring initiatives. The 'Enterprise Excellence' program aims to drive long-term growth and efficiency through optimizing global operations, functions, and commercial processes, with projected gross savings of over $3 billion. Additionally, the 'Simplification' program is streamlining the organizational structure into a portfolio-level model with empowered operating units to accelerate decision-making and enhance competitiveness, targeting annual savings of approximately $450 million to $475 million.
How is Medtronic managing its debt and ensuring financial flexibility?
Medtronic maintains a strong liquidity position with $3.6 billion in cash and cash equivalents and $7.2 billion in current investments as of April 30, 2021. The company also has access to a $3.5 billion credit facility. Total debt increased to $26.4 billion, primarily due to the issuance of Euro-denominated senior notes and debt redemptions. Despite the debt levels, the company's credit ratings remain strong, and management believes its liquidity sources and cash flow generation capabilities are sufficient to meet its foreseeable operating needs and capital allocation strategies.
06—Continue